Loading...
| A03794 | Pages: NA | Feb 2022 | 4154 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Genomic Biomarkers Market
Request Now !Biomarkers are minimally or non-invasive tools used in imaging technology to provide clear imaging of oncology tumors & other problems and also eliminate the chance of radiation exposure during imaging through CT scans and MRI scans. Genomic biomarkers are used to test high blood pressure, hyperkalemia, and other monogenic conditions. They reflect the expression of a gene, function of a gene, and regulation of a gene in normal biologic processes, pathogenic processes, and responses to therapeutics.
The major factors that contribute to the growth of the genomic biomarkers market include increasing prevalence of ovarian, gastric, and colorectal cancers, high demand for minimally invasive procedures, development of technologies in clinical laboratory tests, immense developments in infrastructure for data sharing and analysis such as bioinformatics, and growing awareness about genomics biomarker-based personalized medicines.
However, complex processes associated with genomics biomarker and stringent government regulations hamper the growth of the global genomic biomarkers market. Growing awareness about the role of biomarkers to diagnose fatal diseases such as cancer and cardiovascular diseases & reimbursement issues are being solved with the intervention of regulatory authorities, which is expected to propel the growth of the market in the near future.
The global genomic biomarkers market is segmented on the basis of application, end user, and region. On the basis of application, the market is segmented into oncology, cardiovascular diseases, neurological diseases, and others. On the basis of end user, the market is segmented into diagnostic & research laboratories, hospitals, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players that operate in this market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Aepodia SA, Myriad Genetics, Inc., Eurofins Scientific, QIAGEN, Bio-Rad Laboratories, Inc., Genomic Health, Liquid Genomics, Epigenomics AG, and AROS Applied Biotechnology A/S.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 GENOMIC BIOMARKERS MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ONCOLOGY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. CARDIOVASCULAR DISEASES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. NEUROLOGICAL DISEASES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 GENOMIC BIOMARKERS MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DIAGNOSTIC & RESEARCH LABORATORIES
5.2.1. Market size and forecast
5.3. HOSPITALS
5.3.1. Market size and forecast
CHAPTER 6 GENOMIC BIOMARKERS MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America genomic biomarkers market by application
6.2.5. North America genomic biomarkers market by end user
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe genomic biomarkers market by application
6.3.5. Europe genomic biomarkers market by end user
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific genomic biomarkers market by application
6.4.5. Asia-Pacific genomic biomarkers market by end user
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA genomic biomarkers market by application
6.5.5. LAMEA genomic biomarkers market by end user
CHAPTER 7 COMPANY PROFILES
7.1. THERMO FISHER SCIENTIFIC INC.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. F. HOFFMANN-LA ROCHE AG
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. AEPODIA SA
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. MYRIAD GENETICS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. EUROFINS SCIENTIFIC
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. QIAGEN
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. BIO-RAD LABORATORIES, INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. GENOMIC HEALTH
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. EPIGENOMICS AG
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. AROS APPLIED BIOTECHNOLOGY A/S
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
